If there was one Pill that I wish the FDA would approve it would be this one…

DES and the Truth: The Bitter Pill

The Truth is the Hardest Pill to Swallow
The Pill of Truth

If there was one pill that I wish the FDA would approve it would be this one: the Pill of Truth …

Read The Truth about Diethylstilbestrol, by John Krueger, May 9, 2012
Find all our posts about DES and the DES-exposed
More about Prescriptions Drugs – the FDA – the Pharmaceutical Industry

On Flickr®

Watch the Diaporama, and the Art photo set on  DES Diethylstilbestrol's photostream on Flickr

If you already have a flickr® account, add us as a contact
Email your photos to des.daughter@gmail.com with a short description and title :-)

My Family of Fur Babies…

Accepting that I’ll never have my own children

My family of fur babies
Personal Stories

My name is Joyce. I always assumed that I’d get married and have kids one day, but that hasn’t happened for me. I’m 49 years old, single and I don’t have kids. It’s not that I didn’t want children – but having kids…

Continue reading My family of fur babies
on MyFertilityChoices.com, Personal Stories – also on Twitter

Related post; Accepting that I’ll never have my own children.

More about Fertility – IVF – Pregnancy – Surrogacy.

Sadly for many DES daughters having their own children is not possible! Many of us who have experienced miscarriages, want to have kids but are struggling or unable to…

Womb Cancer Information Leaflet

If you have any concerns about womb cancer please speak to your G.P.

It’s a tough one. We talk about sexual health these days in such open terms, but I feel that people just aren’t yet ready to talk about gynaecological cancers.

Womb Cancer Information Leaflet
If you have any concerns about womb cancer please speak to your G.P.

Download The Eve Appeal Womb Cancer Information Leaflet
By The Eve Appeal gynaecology cancer research fund, London UK – on Facebook and Twitter

Watch the Diaporama, and the DES research photo set on flickr®  DES Diethylstilbestrol's photostream on Flickr

If you already have a flickr® account, add us as a contact
Email your photos to des.daughter@gmail.com with a short description and title :-)

Our Posts about – Endometrial Cancer – Womb Cancer – Women’s Health

In Utero Exposure to DES or BPA increases EZH2 Expression in the Mammary Gland

In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer

BPA-and-DES molecular image
DES and BPA are estrogen-like endocrine-disrupting chemicals that induce persistent epigenetic changes in the developing uterus.

Abstract:

Diethylstilbestrol (DES) and Bisphenol-A (BPA) are estrogen-like endocrine-disrupting chemicals that induce persistent epigenetic changes in the developing uterus. However, DES exposure in utero is also associated with an increased risk of breast cancer in adult women. Similarly, fetal exposure to BPA induces neoplastic changes in mammary tissue of mice. We hypothesized that epigenetic alterations would precede the increased risk of breast neoplasia after in utero exposure to endocrine disruptors. Enhancer of Zeste Homolog 2 (EZH2) is a histone methyltransferase that has been linked to breast cancer risk and epigenetic regulation of tumorigenesis. We examined the effect of BPA and DES on EZH2 expression and function in MCF-7 cells and in mammary glands of mice exposed in utero. DES and BPA treatment approximated human exposure. EZH2 functional activity was assessed by measuring histone H3 trimethylation. Treatment of MCF-7 cells with DES or BPA led to a 3- and 2-fold increase in EZH2 mRNA expression, respectively (p < 0.05) as well as increased EZH2 protein expression. Mice exposed to DES in utero showed a >2-fold increase in EZH2 expression in adult mammary tissue compared with controls (p < 0.05). EZH2 protein was elevated in mammary tissue of mice exposed to DES or BPA. Histone H3 trimethylation was increased in MCF-7 cells treated with BPA or DES. Similarly, mice exposed to BPA or DES in utero showed increased mammary histone H3 trimethylation. Developmental programming of EZH2 is a novel mechanism by which in utero exposure to endocrine disruptors leads to epigenetic regulation of the mammary gland.

Conclusion

We have demonstrated a novel mechanism by which endocrine-disrupting chemicals regulate developmental programming in the breast. Exposure to DES or BPA in utero alters mammary tissue expression of EZH2, a histone methyltransferase with known associations to tumorigenesis. EZH2 function, measured by examination of histone H3 (tri methyl K27), also increases as a result of exposure to DES or BPA. Increased expression of EZH2 within the breast, even in morphologically normal appearing tissue, may prove to be a marker of increased breast cancer risk. The increase in EZH2 expression and function shown here in mice after in utero exposure to these chemicals is a potential mechanism for the increased risk of breast cancer as a result of exposure to these EDCs. This study also generates important safety concerns about exposures to environmental endocrine disruptors such as BPA and suggests a potential need to monitor women exposed to these chemicals for the development of breast lesions as adults.

Sources and full study
  • In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer, NCBI PMID: 21761357, Horm Cancer. 1(3):146-55. doi: 10.1007/s12672-010-0015-9, 2010 Jun.
  • Full text PMCID: PMC3140020, NIHMSID: NIHMS309412, doi: 10.1007/s12672-010-0015-9, Jul 20, 2011.
More DES DiEthylStilbestrol Resources

Prevalence of Autism Spectrum Disorders ASDs among multiple Areas of the USA in 2008

More children than ever before – 1 in 88 – are being diagnosed with autism spectrum disorders

Community Report From the Autism and Developmental Disabilities Monitoring, ADDM Network 2012
More children than ever before – 1 in 88 – are being diagnosed with autism spectrum disorders (ASDs).

The Centers for Disease Control and Prevention (CDC) estimates that about 1 in 88 children has been identified with an autism spectrum disorder (ASD). CDC’s estimate comes from the Autism and Developmental Disabilities Monitoring (ADDM) Network, which monitors the number of 8-year-old children with ASDs living in diverse communities throughout the United States. In 2007, CDC’s ADDM Network first reported that about 1 in 150 children had an ASD (based on children who were 8 years old in 2002). Then, in 2009, the ADDM Network reported that 1 in 110 children had an ASD (based on children who were 8 years old in 2006). Most recently, the ADDM Network reported that 1 in 88 children had an ASD (based on children who were 8 years old in 2008). This means that the estimated prevalence of ASDs increased 23% during 2006 to 2008 and 78% during 2002 to 2008 (1–4).

The community report Prevalence of Autism Spectrum Disorders– Autism and Developmental Disabilities Monitoring Network United States 2008 covers:

  • Executive summary
  • What are autism spectrum disorders?
  • Why do we need to know how many people have ASDs ?
  • What is the ADDM network?
  • Results
  • State by state
  • How can the data be used?
  • Questions and answers
  • What else do I need to know?
  • Where can I get more information?

Read Community Report From the Autism and Developmental Disabilities Monitoring, CDC, ADDM Network 2012.  Find out more about autism.

Douze signes du cancer du sein à (re)connaître #BreastCancer

Essayez ce questionnaire de santé féminine

Pouvez-vous citer douze signes du cancer du sein?

Cette image de Corrine Beaumont, graphic designer, nous montre à quoi le cancer du sein ressemble et nous informe d’une manière simple et efficace.

Tentez de trouver les réponses avant de regarder les solutions ci-dessous…

Une douzaine de signes du cancer du sein
Une douzaine de signes du cancer du sein – crédit @MayorGirl

Sources: Flickrblogwebsite

Réponses:
A: durcissement B: rétraction C: érosion cutanée D: rougeur ou chaleur
E: écoulement F: fossette G: bosse, enflure H: veine apparente
I: mamelon inversé J: asymétrie K: peau de “pelure d’orange” L: masse interne

En savoir plus:

Fetal Valproate Syndrome in a Two Month Old Male Infant

FVS is characterized by a distinctive facial appearance, a cluster of minor and major anomalies and central nervous system dysfunction

Fetal valproate syndrome in a 2-month-old male infant
The Annals of Saudi Medicine is an international, peer-reviewed medical journal published by the King Faisal Specialist Hospital and Research Centre, Riyadh,KSA

Abstract:
Fetal valproate syndrome (FVS) results from prenatal exposure to valproic acid.
It is characterized by a distinctive facial appearance, a cluster of minor and major anomalies and central nervous system dysfunction.
We describe a 2-month-old male infant with the typical dysmorphic features characteristic of FVS. He had a persistent left superior vena cava draining into a dilated coronary sinus and mild pulmonary hypertension. There was a history of maternal intake of sodium valproate during pregnancy.

Valproic acid (VPA) is a widely used antiepileptic drug and mood stabilizer. It was first introduced for use as an antiepileptic drug in 1964 and is still a commonly used antiepileptic drug (AED) worldwide. A description of the teratogenic effect of the drug was first published in 1980. Since then many potential teratogenic and dysmorphogenic effects of VPA have been reported. We report a case of fetal valproate syndrome (FVS) in a 2-month-old male infant born of an epileptic mother who was taking sodium valproate during pregnancy.

For Case Study and Discussion, read Fetal valproate syndrome in a 2-month-old male infant, NCBI, Ann Saudi Med. 2010 May-Jun; 30(3): 233–235. PMCID: PMC2886875

For Related Posts, see our Tags:
AEDs – Epilepsy – NCBI – Pregnancy
Drugs – Dépakine – Epilim – Topiramate – Valproate

An Introduction to the Health Effects of Endocrine Disrupting Chemicals

The chemical cocktail that enters our body from food, drink and pollution

DES Daughter Network on SlideShare

Watch the video: Endocrine Disruptors: Sexy Stuff
All our posts about BPA – Endocrine Disruptors – Pesticides – Phthalates

Mastectomy Patients: meet the 3D Nipple Tattoos Michelangelo

Vinnie Myers, the tattoo artist transforming mastectomy patients’ scarred chests with incredible three-dimensional nipple inkings

In a small town north of Baltimore, a man has made a career out of making women become whole again. After preventative mastectomies, women are left with, usually, a reconstruction, but no nipples. Vinnie Myers of Little Vinnie’s Tattoo Shop helps clients traveling from all parts of the world who want to get his one of a kind 3D nipple tattoos.

Related articles:

Frequently Asked Questions:

  • When can I get nipple tattoos done?
  • Is it possible to tattoo a reconstructed nipple?
  • If you have implant-only reconstruction, is there any risk for the tattoo needle accidentally puncturing the implant?
  • Can you correct a tattoo done in the plastic surgeon’s office?
  • What’s the difference between inks used in the doctor’s office and tattoo shops?
  • Will getting a nipple tattoo hurt?
  • How much can I expect one or two nipple tattoos to cost?
  • How do I find a tattoo artist to do my tattoos?
  • Do I need a consultation with the tattoo artist ahead of time?
  • How long will it take to create the tattoo?
  • How long will the tattoo(s) take to heal?
  • How does the color of the tattoo change over time?
  • Read Vinnie Myers, 3-D Nipple Tattoo Artist: FAQs,
    BreastCancer.org, September 4th, 2013
  • UK Contact: Richard Burley website

Related posts: